

Research Article

A Study on Cytotoxic and Apoptotic Potential of a Triterpenoid Saponin (3-O-α-L-Arabinosyl Oleanolic Acid) Isolated from *Schumacheria castaneifolia* Vahl in Human Non-Small-Cell Lung Cancer (NCI-H292) Cells

Sameera R. Samarakoon,¹ Meran K. Ediriweera,¹ Chukwumaobim Daniel Uzochukwuwulu Nwokwu,¹ Chamara Janaka Bandara,^{1,2} Kamani H. Tennekoon,¹ Poorna Piyathilaka,³ D. Nedra Karunaratne,² and Veranja Karunaratne^{2,4}

¹Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, 90 Cumaratunga Munidasa Mawatha, 03 Colombo, Sri Lanka

²Department of Chemistry, Faculty of Science, University of Peradeniya, Peradeniya, Sri Lanka

³Department of Biotechnology, Faculty of Agriculture and Plantation Management, Wayamba University of Sri Lanka,

Makadura, Gonawila, Sri Lanka

⁴Sri Lanka Institute of Nanotechnology, Mahenwatta, Pitipana, Homagama, Sri Lanka

Correspondence should be addressed to Sameera R. Samarakoon; sam@ibmbb.cmb.ac.lk

Received 21 July 2017; Revised 6 October 2017; Accepted 23 October 2017; Published 13 November 2017

Academic Editor: Gang Liu

Copyright © 2017 Sameera R. Samarakoon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lung cancer is the major cause of cancer death among men. A number of natural compounds have proven to be useful in the treatmet of lung cancer. This study was aimed to determine cytotoxic and apoptotoic effects of a natural compound 3-O- α -L-arabinosyl oleanolic acid (3-O-L-AO) isolated from *Schumacheria castaneifolia* in non-small-cell lung cancer (NCI-H292) cells. Cytotoxic effects of 3-O-L-AO were determined by Sulforhodamine B (SRB) assay and apoptotic effects were tested by evaluating (a) apoptotsis related morphological changes, (b) caspase 3/7 activity, and (c) expression of *Bax, p53, and survivin* genes. Oxidative stress markers (reactive oxygen species (ROS), glutathione-S-transferase (GST), and glutathione (GSH)) were also analysed in 3-O-L-AO treated NCI-H292 cells. 3-O-L-AO exerted potent cytotoxic effects in NCI-H292 cells while being less cytotoxic to normal lung (MRC-5) cells. Exposure to 3-O-L-AO caused upregulation of *Bax* and *p53* and downregulation of *survivin* in NCI-H292 cells. Activation of caspase 3/7 and morphological features related to apoptosis further confirmed 3-O-L-AO induced apoptosis. Furthermore, elevated ROS and GST levels and decreased GSH levels suggest day O-L-AO can induce apoptosis, possibly causing oxidative stress in NCI-H292 cells. Overall results suggest that 3-O-L-AO can be considered as an effective anticancer agent for the treatment of lung cancer.

1. Introduction

Lung cancer ranks as the second most commonly diagnosed cancer and major cause of cancer death among men worldwide [1, 2]. Non-small-cell lung cancer (NSCLC) and smallcell lung cancer (SCLC) are the two major types of lung cancer [3]. Non-small-cell lung cancer is the most common form of lung cancer accounting for 85 to 90% of cases [3]. Smoking, genetic factors, some toxic gases, heavy metals, air pollution, and radon gas are implicated as main causes for lung cancer [2]. Radiotherapy, chemotherapy, immunotherapy, and surgery are the commonly used treatment options for lung cancer. Although chemotherapy is the most commonly used treatment, several drawbacks are associated with chemotherapeutic agents such as toxicity, limited efficacy, and drug resistance [2]. Therefore, it is essential to search for new



FIGURE 1: Chemical structure of 3-O-α-L-arabinosyl oleanolic acid (3-O-L-AO).

treatment options for lung cancer with fewer side effects. Plants have been recognized as the main source of drugs for many diseases including cancer since ancient times and plant based remedies are known to cause less side effects [4]. Many plant crude extracts have been identified as cytotoxic to cancer cells. However, identification of compounds from such crude extracts with anticancer effects and elucidation of their molecular pathway(s) of action are mandatory for future development of these extracts as cancer therapeutics. Currently used anticancer drugs such as taxol, camptothecin, epipodophyllotoxin, and vinblastine are derived from plant sources and there are several more plant derived anticancer compounds in clinical trials [5].

Sri Lanka is a biodiversity hotspot with 894 endemic plant species, thus providing a rich source to identify novel drug leads [6]. Schumacheria castaneifolia (family Dilleniaceae) which is mainly found in rain forests is a plant endemic to Sri Lanka [7]. A recent study carried out by Jayarathna et al., 2016 [6], has shown cytotoxic and antioxidant effects of chloroform and ethyl acetate extracts of stem bark of S. castaneifolia in estrogen receptor positive (MCF-7) and triple negative breast cancer (MDA-MB-231) cells. Another study conducted by Pamunuwa et al., 2015 [8], has reported antioxidant properties of liposomal nanoparticles prepared from the methanol extract of stem bark of S. castaneifolia. Isolation and structure elucidation of of several compounds from the leaves of S. castaneifolia have also been reported [9, 10]. 3- $O-\alpha$ -L-Arabinosyl oleanolic acid (3-O-L-AO), a triterpenoid saponin, is one of the compounds isolated from leaves of S. castaneifolia (Figure 1). Moderate antibacterial effects of 3-O-L-AO against Staphylococcus aureus and Escherichia coli have been reported [9]. However, there are no investigations on anticancer properties of 3-O-L-AO. Therefore, the present study was designed to evaluate possible in vitro anticancer effects of 3-O-L-AO in non-small-cell lung cancer cells (NCI-H292).

2. Materials and Methods

2.1. Materials. Medium (Dulbecco's Modified Eagle's Medium (DMEM)) required for cell culture was purchased from Invitrogen (Carlsbad, CA, USA). Two cell lines (NCI-H292 (small-cell lung cancer cells) and MRC-5 (normal human lung fibroblast cells)) and fetal bovine serum (FBS) were purchased from American Type Culture Collection (ATCC), Rockville, MD, USA. Caspase-Glo 3/7 assay kit and all the reagents required for cDNA synthesis were purchased from Promega, USA. All other chemicals used in this study were purchased from Sigma Aldrich Chemical (St. Louis, MO, USA) unless otherwise indicated. 3-O-L-AO isolated in a previous study carried out by Bandara et al. 2015 was used for the present study [9].

2.2. Cell Culture. Two cell lines were cultured in DMEM supplemented with 10% FBS and 0.1% antibiotics in T-25 flasks. Flasks were incubated in a humidified atmosphere of 5% CO₂ at 37° C.

2.3. Cytotoxicity Assays. Sulphorhodamine B (SRB) assay [11, 12] was used to dertmine cytotoxic effects of the compound (3-O-L-AO) in NCI-H292 and MRC-5 cells. Cells (5 \times 10³/well) were seeded in 96-well tissue culture plates and incubated for 24 h. After 24 h incubation, cells were treated with 3-O-L-AO (0.78–25 μ g/mL) and incubated for 24, 48, and 72 h. Paclitaxel (0.47–15 μ g/mL) was used as the positive control. Cells were washed with PBS for three times and then fixed by adding 50% trichloroacetic acid (TCA) to each well followed by washing five times with tap water. After fixing, cells were stained with 0.4% SRB dye for 20 min followed by washing five times with 1% acetic acid. Tris-base (10 mM) was then added to each well and plates were kept on a plate shaker for 1h at room temperature. The absorbance was measured using a microplate reader (Synergy HT, USA) at wavelength of 540 nm.

2.4. Morphological Changes. Morphological changes of lung cancer cells (NCI-H292) and normal fibroblasts (MRC-5) cells after exposure to 3-O-L-AO were captured using inverted phase-contrast microscope (Olympus CKX41, Japan).

2.5. Morphological Changes Related to Apoptosis Observed under Fluorescence Microscopy. NCI-H292 lung cancer cells $(2 \times 10^4 \text{ cells/well})$ cultured on coverslips were treated with 3-O-L-AO (2.5, 5, and 10 µg/mL) for 24 h. After incubation, cells were washed with phosphate buffer saline (PBS) and fixed with 4% formaldehyde for 15 min. Fixed cells were again washed with PBS and stained with acridine orange/ethidium

Cell type	3-O-L-AO (µg/mL)			Paclitaxel (µg/mL)		
	24 h	48 h	72 h	24 h	48 h	72 h
NCI-H-292	4.33	2.69	1.50	8.37	3.28	1.59
MRC-5	5.40	4.59	2.83	1.51	0.96	0.35

TABLE 1: IC₅₀ values (μ g/mL) of 3-O-L-AO in NCI-H292 and MRC-5 cells at 24, 48, and 72 h incubation periods.

bromide as previously described by us [11]. Stained cells were observed under a fluorescence microscope (Olympus, BX51TRF, Japan).

2.6. Caspase 3/7 Activity Assay. Caspase 3/7 activity in NCI-H292 cells was measured using the Caspase-Glo 3/7 assay kit according to manufacturer's protocol [11]. Prior to the assay, NCI-H292 cells were treated with three doses of 3-O-L-AO (0.5, 1, and 2 μ g/mL) and incubated for 24 h.

2.7. Oxidative Stress Markers. Evaluation of oxidative stress markers (reactive oxygen species (ROS), glutathione-S-transferase (GST), and glutathione (GSH)) after exposure to 3-O-L-AO in NCI-H292 cells was determined as previously described by us [11].

2.8. Reactive Oxygen Species (ROS). NCI-H292 cells (20,000 cells/well) were plated in 96-well cell plates and incubated for 24 h. Following incubation, cells were treated with 3-O-L-AO (0.5, 1, and 2 μ g/mL) and incubated for 24 h. Nitro Blue Tetrazolium (NBT) solution (1 mg/mL, 20 μ L) was then added to each well and incubated for 1 h at 37°C. Blue formazan formed was then solubalized after adding 100 μ L of dimethyl sulfoxide (DMSO) and the absorbance was read at 620 nm.

2.9. Glutathione (GSH) Levels. NCI-H292 cells were $(1 \times 10^5$ cells/well) exposed to 3-O-L-AO (0.5, 1, and 2µg/mL) for 24 h. After incubation, cells were collected by trypsinization. Collected cell pellets were mixed with ice-cold KCl (2 mL) and 0.5 M EDTA (1 mL) and sonicated for two hours. Cell lysate was then centrifuged at 10,000 g for 15 min to obtain a clear supernatant and it was kept on ice throughout the experiments. Supernatent (75 µL) was mixed with 75 µL of 5% sulfosalicylic acid, 20 µL of 4% DTNB [5,5-dithiobis-(2-nitrobenzoic acid)], and 30 µL of 0.1 M potassium phosphate buffer (pH 8.0) and incubated for 30 min. Absorbance was then recorded at 412 nm and glutathione levels were calculated as nM/mg of cell lysate protein with the help of a GSH standard curve.

2.10. Glutathione-S-Transferase Activity (GST). An aliquot of cell lysates prepared for GSH assays was used to analyse GST activity. Glutathione and CDNB (1-chloro-2,4dinitrobenzene) were served as substrates in this assay. A mixture was prepared by mixing 490 μ L of PBS (pH 6.5), 5 μ L of CDNB (100 mM), and 5 μ L of GSH (100 mM); 180 μ L of this mixture was mixed with 20 μ L of cell lysate and incubated for 5 min at 37°C. Absorbance was recoreded at 340 nm for 5 min (1-minute time intervals). Quantity of GST catalyzing the oxidation of 1 millimole of 1-chloro-2,4-dinitrobenzene per minute at 37°C was considerd as one unit of GST activity. 2.11. Quantitative Real-Time PCR. NCI-H292 cells (2×10^5) cells/mL) grown in T-25 tissue culture flasks were treated with 3-O-L-AO (1 and $2\mu g/mL$) and incubated for another 24 h. TRIzol reagent was used to extract RNA as described by Ediriweera et al., 2016 [13]. Extracted RNA $(2 \mu g)$ was incubated with 50 ng of random primers and 13.5 μ L of PCR water for 5 min at 70°C. cDNA synthesis was then carried out after mixing with a maxter mix containing $5 \mu L$ MMLV (Moloney Murine Leukemia Virus Reverse Transcriptase) reaction buffer, 5 µL 10 mM dNTP mix, 25 units of RNasin, and 200 units of MMLV RT enzyme, following incubation at 37°C for 60 min, in a total volume of $25 \,\mu$ L. Stratagene Mx3000P real-time PCR system (Agilent Technologies, CA, USA) was used to carry out real-time PCR. Primers used have been previously described [13]. For real-time PCR, 2 µL of cDNA was mixed with Master Mix containing $0.5 \,\mu$ L of forward and reverses primers, 12.5 µL SYBR Green Master Mix (Eurogentec, Seraing, Liège, Belgium), and $9.5 \,\mu\text{L}$ PCR water. The thermal cycle programme set for real-time PCR include stage 1, 95°C for 10 min and stage two consisting of three steps: denaturation at 95°C for 30 s, annealing at 56°C for 1 min, and extension at 72°C for 30 s and stage 2 was repeated for 40 cycles. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as the internal house keeping gene. Gene expression was quantified using the method described by Livak and Schmittgen, 2001 [14].

2.12. Statistical Analysis. GraphPad Prism 6.0.1 software (GraphPad Software Inc., San Diego, CA, USA) was used for statistical analysis. The results have been expressed as mean \pm SD of three individual experiments. One-way analysis of variance (ANOVA) with Tukey's multiple comparisons test (secondary test) was used to analyse significant differences. p < 0.05 was considered significant.

3. Results and Discussion

3.1. Cytotoxic Potential of 3-O-L-AO in Non-Small-Cell Lung Cancer (NCI-H292) and Normal Lung Fibroblast (MRC-5) Cells. According to the results obtained from the SRB assay (Table 1), it is evident that 3-O-L-AO can inhibit lung cancer cell proliferation in a time dependant manner. Cytotoxic effects of 3-O-L-AO in normal lung fibroblast were less compared to lung cancer cells at all three incubation periods (24, 48, and 72 h). Moreover, 3-O-L-AO exhibited a higher cytotoxic effect in lung cancer cells and a lower cytotoxic effect in normal lung fibroblast cells compared to the positive control paclitaxel. Cytomorphological images (Figure 2) following 3-O-L-AO treatment also illustrated a time and dose-dependent inhibition of lung cancer and normal lung fibroblast cells by 3-O-L-AO. Less amount of cells was



FIGURE 2: Cytomorphological images of NCI-H292 and MRC-5 cells after exposure to 3-O-L-AO. (A1), (B1), (C1), (A2), (B2), and (C2) are untreated controls. (a), (b), (c), (j), (k), and (l) treated with $1.5 \mu g/mL$; (d), (e), (f), (m), (n), and (o) treated with $6.25 \mu g/mL$; and (g), (h), (i), (p), (q), and (r) treated with $12.5 \mu g/mL$.





FIGURE 3: NCI-H292 cells (exposed to 3-O-L-AO) stained with AO/EB and observed under fluorescence microscope showing evidences of apoptosis. (a) Untreated control; (b) treated with 2.5 μ g/mL; (c) treated with 5 μ g/mL; and (d) treated with 10 μ g/mL.

observed in treated experiments when compared to untreated controls. Considerable morphological changes observed in 3-O-L-AO treated lung cancer and lung fibroblast cells such as decreased cell volume and rounding up cells.

3.2. Induction of Apoptosis by 3-O-L-AO in Non-Small-Cell Lung Cancer Cells. As initial cytotoxic assays with 3-O-L-AO confirmed potent cytotoxic effects in non-small-cell lung cancer cells, further studies such as acridine orange (AO) ethidium bromide (EB) staining, estimation of caspase 3 and 7 activities, and evaluation of mRNA expression levels of selected apoptotic related genes cells were carried out to confirm whether exposure of non-small-cell lung cancer cells to 3-O-L-AO can induce apoptosis.

3.2.1. AO/EB Staining. 3-O-L-AO treated NCI-H292 cells stained with AO/EB showed morphological changes of apoptosis. Untreated control cells appeared in green as acridine orange (AO) permeates these cells whereas apoptotic cells stain in yellow/red as ethidium bromide (EB) permeates these cells (Figure 3). Results indicated a dose dependent apoptotic induction in 3-O-L-AO treated NCI-H292 cells.

3.2.2. Caspase 3/7 Activity. Activated caspases 3 and 7 have been recognized as executioner caspases which can initiate apoptosis. Increased caspase 3/7 activity in 3-O-L-AO treated NCI-H292 was observed at 24 h incubation period. Significant (p < 0.0001) increase in caspase 3/7 activity was observed at all three doses tested compared to the untreated control (Figure 4).



FIGURE 4: Caspase 3/7 activation in 3-O-L-AO treated NCI-H292 cells (24 h). *** p < 0.0001.

3.3. Effects of 3-O-L-AO on the Expression of Apoptotic Related Genes. According to the results obtained in the present study, upregulation of tumor suppressor p53 gene was observed in 3-O-L-AO treated NCI-H292 cells at both doses tested (1 and $2 \mu g/mL$). However, significant (p < 0.05) upregulation was only observed at $2 \mu g/mL$ of 3-O-L-AO. Significant (p < 0.001 and p < 0.0001) upregulation of proapoptotic *Bax* gene was also observed in 3-O-L-AO treated NCI-H292 cells at both doses tested (1 and $2 \mu g/mL$). 3-O-L-AO also caused downregulation of survivin gene which can encode an inhibitor of apoptosis at both the doses tested. However this downregulation was not significant (Figure 5).



FIGURE 5: Regulation of apoptosis related genes (*p53, Bax, and survivin*) in NCI-H292 cells after exposure to 3-O-L-AO for 24 h. (*** p < 0.0001; ** p < 0.001).

3.4. Effects of 3-O-L-AO on Oxidative Stress Markers. As shown in Figure 6 reactive oxygen species (ROS) level was significantly (p < 0.05 to p < 0.0001) increased at all three doses (0.5, 1, and $2 \mu g/mL$) in 3-O-L-AO treated NCI-H292 cells in a dose dependant manner. ROS are reactive chemical species containing oxygen which can damage live cells and increase apoptosis. Significant reduction in GSH (p < 0.0001) and increase in GST (p < 0.05 to p < 0.0001) levels were also observed at all three doses (3-O-L-AO) in NCI-H292 cells.

4. Discussion

A number of triterpenoid saponins with various biological properties have been reported by other authors [15-18]. Among them, cytotoxic and apoptotic potential of natural and synthetic triterpenoid saponins have long been illustrated [19, 20]. Triterpenoid saponins, such as α -hederin [21], astragaloside [22], and cucurbitacin [23], are well known examples that have shown promising anticancer effects in several cancer cell lines. However, the present study on the triterpenoid saponin, 3-O-L-AO, is the first study which adressess its cytotoxic and apoptotic potential in lung cancer cells. A compound, with the IC₅₀ value of $4 \mu g/mL$ or $10 \mu M$, is considerd as a potent anticancer compound [24, 25]. As our compund 3-O-L-AO exhibited IC_{50} values in this margin (in non-small lung cancer cells at 24, 48, and 72 h after incubations), this triterpenoid saponin is suitable to be included in the list of effective anticancer drug leads and, thus, deserves further investigations. Paclitaxel was used only in cell viability studies as the positive control. A positive control was not used for other assays (gene expression, caspase 3/7 assay, and oxidative stress markers) as we mainly focused to elaborate anticancer potential of our selected drug 3-O-L-AO.

Apoptosis (programmed cell death) is the mechanism that removes unwanted cells in biological systems [26].



FIGURE 6: Markers of oxidative stress (ROS, GSH, and GST) after treatment of NCI-H292 cells with 3-O-L-AO for 24 h. (a) ROS levels; (b) GST activity; and (c) GSH levels. *** p < 0.0001 and * p < 0.05.

Morphological changes, shrinkage of cells, generation of apoptotic bodies, condensation of chromatin, and loss of cell organelles are associated with apoptosis [27]. Induction of apoptosis can be triggered via extrinsic and intrinsic pathways [28]. Interaction of specific signaling molecules to death receptors causes initiation of extrinsic pathway, while the intrinsic pathway is initiated by extracellular or intracellular stress. Caspases, a class of protease enzymes, play a prominent role in the regulation of apoptosis. Caspases 2, 8, 9, and 10 are known as initiator caspases while caspaes 3, 6, and 7 are executioner caspases [29]. Evading apoptosis is one of the main features of cancer cells [30]. Therefore, exploration of natural compounds with the ability to induce apoptosis in cancer cells has gained much attention. In the present study apoptotic effects of 3-O-L-AO in NCI-H292 cells were confirmed by observing morphological changes and analysing caspase 3/7 activity. Apart from caspases, several gene products are reported to be involved in apoptosis. Among them, Bcl-2 family of proteins such as Bax (proapoptotic) and Bcl-2 (antiapoptotic) are main proteins in the intrinsic pathway of apoptosis [31]. Activation of initiator caspases is regulated via Bax. In apoptosis, p53 (tumor suppressor gene) is activated through the activation of Bax, a Bcl-2 family member [32]. Survivin, an antiapoptotic protein, is also reported to be regulated by p53 [33]. In the present study, a dose-dependent upregulation of Bax and p53 was observed at both the doses in 3-O-L-AO treated NCI-H292 cells at 24 h incubation. However, upregulation of p53 was only observed at the highest dose. Downregulation of survivin was observed at both the doses tested. However this downregulation was not significant. Induction of apoptosis in cancer cells by generation of reactive oxygen species (ROS) and reduction of endogenous antioxidants has been well discussed [34]. Drugs that generate ROS in cancer cells have been considerd as potential therapeutic strategies to target cancer [35]. Cellular glutathione (GSH) levels are reported to act as protective substances against oxidative stress induced injuries [36]. Therefore, reduction in GSH levels enhances susceptibility to oxidative stress mediated cytotoxicity [37]. GSH conjugate formation with toxic materials in metabolic pathways is catalyzed by glutathione S-transferases (GSTs) [38]. Increase in ROS and GST levels and concomitant decrease in cellular GSH levels imply possible activation of an oxidative stress mediated apoptotic pathway in 3-O-L-AO treated NCI-H292 cells.

5. Conclusion

According to the results obtained in the present study, 3-O-L-AO appears to mediate cytotoxic and apoptotic effects through activation of an oxidative stress mediated mechanism in non-small lung cancer cells (NCI-H292). This study provides a rationale for future investigation of anticancer effects of 3-O-L-AO in other *in vitro* and *in vivo* models.

Conflicts of Interest

The authors report no conflicts of interest in this work.

Acknowledgments

Financial support given by Institute of Biochemistry Molecular Biology and Biotechnology, University of Colombo, and National Science Foundation, Sri Lanka (RPHS/2016-C07), is gratefully acknowledged.

References

- R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2017," CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017.
- [2] L. A. Torre, R. L. Siegel, and A. Jemal, "Lung cancer statistics," Advances in Experimental Medicine and Biology, vol. 893, pp. 1– 19, 2016.
- [3] M. Saito, K. Shiraishi, H. Kunitoh, S. Takenoshita, J. Yokota, and T. Kohno, "Gene aberrations for precision medicine against lung adenocarcinoma," *Cancer Science*, vol. 107, no. 6, pp. 713– 720, 2016.
- [4] M. H. Carlsen, B. L. Halvorsen, K. Holte et al., "The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide," *Nutrition Journal*, vol. 9, no. 1, article 3, 2010.
- [5] M. J. Balunas and A. D. Kinghorn, "Drug discovery from medicinal plants," *Life Sciences*, vol. 78, no. 5, pp. 431–441, 2005.
- [6] P. P. Jayarathna, K. H. Tennekoon, S. R. Samarakoon et al., "Cytotoxic, antioxidant and apoptotic effects of twenty sri lankan endemic plants in breast cancer cells," *European Journal* of Medicinal Plants, vol. 15, no. 1, pp. 1–15, 2016.
- [7] N. Gunatilleke, R. Pethiyagoda, and S. Gunatilleke, "Biodiversity of Sri Lanka," *Journal of the National Science Foundation of Sri Lanka*, vol. 36, pp. 25–62, 2008.
- [8] K. M. G. K. Pamunuwa, C. J. Bandara, V. Karunaratne, and D. N. Karunaratne, "Optimization of a liposomal delivery system for the highly antioxidant methanol extract of stem-bark of Schumacheria castaneifolia Vahl," *Journal of Chemical and Pharmaceutical Research*, vol. 4, pp. 1236–1245, 2015.
- [9] C. J. Bandara, A. Wickramasinghe, B. M. R. Bandara, D. N. Karunaratne, D. S. A. Wijesundara, and V. Karunaratne, "Chemistry and bioactivity of compounds of genus Schumacheria and its close chemotaxonomic relationship to the genus Dillenia," *Journal of Chemical and Pharmaceutical Research*, vol. 7, no. 10, pp. 586–592, 2015.
- [10] A. A. Gurni and K. Kubitzki, "Flavonoid chemistry and systematics of the Dilleniaceae," *Biochemical Systematics and Ecology*, vol. 9, no. 2-3, pp. 109–114, 1981.
- [11] M. K. Ediriweera, K. H. Tennekoon, S. R. Samarakoon, I. Thabrew, and E. D. de Silva, "Induction of apoptosis in MCF-7 breast cancer cells by sri lankan endemic mango (*Mangifera zeylanica*) fruit peel through oxidative stress and analysis of its phytochemical constituents," *Journal of Food Biochemistry*, 2016.
- [12] S. R. Samarakoon, I. Thabrew, P. B. Galhena, and K. H. Tennekoon, "Modulation of apoptosis in human hepatocellular carcinoma (HepG2 cells) by a standardized herbal decoction of Nigella sativa seeds, Hemidesmus indicus roots and Smilax glabra rhizomes with anti- hepatocarcinogenic effects," BMC Complementary and Alternative Medicine, vol. 12, article 25, 2012.
- [13] M. K. Ediriweera, K. H. Tennekoon, S. R. Samarakoon, I. Thabrew, and E. D. de Silva, "A study of the potential anticancer activity of Mangifera zeylanica bark: Evaluation of cytotoxic and apoptotic effects of the hexane extract and bioassay-guided fractionation to identify phytochemical constituents," *Oncology Letters*, vol. 11, no. 2, pp. 1335–1344, 2016.
- [14] K. J. Livak and T. D. Schmittgen, "Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta Ct}$ method," *Methods*, vol. 25, no. 4, pp. 402–408, 2001.
- [15] T. Khanal, J. H. Choi, Y. P. Hwang, Y. C. Chung, and H. G. Jeong, "Saponins isolated from the root of Platycodon grandiflorum"

protect against acute ethanol-induced hepatotoxicity in mice," *Food and Chemical Toxicology*, vol. 47, no. 3, pp. 530–535, 2009.

- [16] K. J. Lee, J. H. Choi, H. G. Kim et al., "Protective effect of saponins derived from the roots of Platycodon grandiflorum against carbon tetrachloride induced hepatotoxicity in mice," *Food and Chemical Toxicology*, vol. 46, no. 5, pp. 1778–1785, 2008.
- [17] X. Chen, J. Lu, W. He et al., "Antiperoxidation activity of triterpenoids from rhizome of Anemone raddeana," *Fitoterapia*, vol. 80, no. 2, pp. 105–111, 2009.
- [18] C. Liang, Y. Ding, H. T. Nguyen et al., "Oleanane-type triterpenoids from Panax stipuleanatus and their anticancer activities," *Bioorganic & Medicinal Chemistry Letters*, vol. 20, no. 23, pp. 7110–7115, 2010.
- [19] A. V. Rao and D. M. Gurfinkel, "The bioactivity of saponins: triterpenoid and steroidal glycosides," *Drug Metabolism and Drug Interactions*, vol. 17, no. 1-4, pp. 211–236, 2000.
- [20] A. Osbourn, R. J. M. Goss, and R. A. Field, "The saponins-polar isoprenoids with important and diverse biological activities," *Natural Product Reports*, vol. 28, no. 7, pp. 1261–1268, 2011.
- [21] L. Cheng, T.-S. Xia, Y.-F. Wang et al., "The anticancer effect and mechanism of α-hederin on breast cancer cells," *International Journal of Oncology*, vol. 45, no. 2, pp. 757–763, 2014.
- [22] W.-J. Zhang, P. Hufnagl, B. R. Binder, and J. Wojta, "Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-κB activation and adhesion molecule expression," *Thrombosis and Haemostasis*, vol. 90, no. 5, pp. 904–914, 2003.
- [23] N. H. Thoennissen, G. B. Iwanski, N. B. Doan et al., "Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells," *Cancer Research*, vol. 69, no. 14, pp. 5876–5884, 2009.
- [24] J. Boik, Natural Compounds in Cancer Therapy, Oregon Medical Press, Minnestota, USA.
- [25] G. Brahemi, F. R. Kona, A. Fiasella et al., "Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast cancer," *Journal of Medicinal Chemistry*, vol. 53, no. 7, pp. 2757–2765, 2010.
- [26] X. Jiang, H. Jiang, Z. Shen, and X. Wang, "Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis," *Proceedings of the National Acadamy of Sciences of the United States of America*, vol. 111, no. 41, pp. 14782–14787, 2014.
- [27] J. Li and J. Yuan, "Caspases in apoptosis and beyond," Oncogene, vol. 27, no. 48, pp. 6194–6206, 2008.
- [28] C. Rana, H. Piplani, V. Vaish, B. Nehru, and S. N. Sanyal, "Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer," *Molecular and Cellular Biochemistry*, vol. 402, no. 1-2, pp. 225–241, 2015.
- [29] J. Lopez and S. W. G. Tait, "Mitochondrial apoptosis: killing cancer using the enemy within," *British Journal of Cancer*, vol. 112, pp. 957–962, 2015.
- [30] S. Elmore, "Apoptosis: a review of programmed cell death," *Toxicologic Pathology*, vol. 35, no. 4, pp. 495–516, 2007.
- [31] H. W. Findley, L. Gu, A. M. Yeager, and M. Zhou, "Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia," *Blood*, vol. 89, no. 8, pp. 2986–2993, 1997.

- [32] A. Mirza, M. McGuirk, T. N. Hockenberry et al., "Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway," *Oncogene*, vol. 21, no. 17, pp. 2613–2622, 2002.
- [33] R. J. Youle and A. Strasser, "The BCL-2 protein family: opposing activities that mediate cell death," *Nature Reviews Molecular Cell Biology*, vol. 9, no. 1, pp. 47–59, 2008.
- [34] J. St-Pierre, S. Drori, M. Uldry et al., "Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators," *Cell*, vol. 127, no. 2, pp. 397–408, 2006.
- [35] A. C. Rego and C. R. Oliveira, "Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases," *Neurochemical Research*, vol. 28, no. 10, pp. 1563–1574, 2003.
- [36] H. J. Forman, H. Zhang, and A. Rinna, "Glutathione: overview of its protective roles, measurement, and biosynthesis," *Molecular Aspects of Medicine*, vol. 30, no. 1-2, pp. 1–12, 2009.
- [37] D. A. Dickinson and H. J. Forman, "Cellular glutathione and thiols metabolism," *Biochemical Pharmacology*, vol. 64, no. 5-6, pp. 1019–1026, 2002.
- [38] C. Gorrini, I. S. Harris, and T. W. Mak, "Modulation of oxidative stress as an anticancer strategy," *Nature Reviews Drug Discovery*, vol. 12, no. 12, pp. 931–947, 2013.



Journal of Toxins

N





Hindawi

Submit your manuscripts at https://www.hindawi.com



Autoimmune Diseases





Anesthesiology Research and Practice





Advances in Pharmacological

Sciences

Emergency Medicine



BioMed Research International



Pain Research and Treatment



Journal of Pharmaceutics





International Journal of Medicinal Chemistry



Journal of Addiction





Stroke Research and Treatment

